Asthika Goonewardene
Stock Analyst at Truist Financial
(3.52)
# 2,215
Out of 4,457 analysts
322
Total ratings
41.4%
Success rate
3.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asthika Goonewardene
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVBP ArriVent BioPharma | Reiterated: Buy | $45 → $32 | $34.37 | -7.65% | 5 | Jun 22, 2026 | |
| ACET Adicet Bio | Reiterated: Buy | n/a | $8.56 | - | 14 | Mar 16, 2026 | |
| ALLO Allogene Therapeutics | Maintained: Buy | $10 | $2.22 | +350.45% | 20 | Mar 13, 2026 | |
| BNTX BioNTech SE | Maintained: Buy | $155 | $94.26 | +64.44% | 19 | Mar 13, 2026 | |
| LEGN Legend Biotech | Maintained: Buy | $70 | $29.39 | +138.18% | 10 | Mar 13, 2026 | |
| RVMD Revolution Medicines | Maintained: Buy | n/a | $192.62 | - | 9 | Mar 9, 2026 | |
| CRBU Caribou Biosciences | Reiterated: Buy | $7 | $1.77 | +295.48% | 11 | Mar 9, 2026 | |
| CGEN Compugen | Reiterated: Buy | $4 | $2.16 | +85.19% | 20 | Mar 3, 2026 | |
| ZYME Zymeworks | Reiterated: Buy | $40 | $24.12 | +65.84% | 4 | Mar 3, 2026 | |
| SEPN Septerna | Maintained: Buy | n/a | $34.75 | - | 1 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $31.08 | -3.47% | 22 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $4.21 | - | 28 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 | $26.02 | +84.47% | 40 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 | $14.32 | +144.41% | 19 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $51 | $54.28 | -6.04% | 30 | Jan 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $8 | $1.65 | +384.85% | 25 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $33.35 | - | 17 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $127 → $145 | $126.33 | +14.78% | 12 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $212.64 | n/a | 1 | Apr 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $7.53 | n/a | 4 | Mar 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.6063 | n/a | 6 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $19 → $15 | $1.75 | n/a | 3 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | kr 269.14 → kr 347.92 | $1,681.64 | n/a | 2 | Jul 14, 2022 |
ArriVent BioPharma
Jun 22, 2026
Reiterated: Buy
Price Target: $45 → $32
Current: $34.37
Upside: -7.65%
Adicet Bio
Mar 16, 2026
Reiterated: Buy
Price Target: n/a
Current: $8.56
Upside: -
Allogene Therapeutics
Mar 13, 2026
Maintained: Buy
Price Target: $10
Current: $2.22
Upside: +350.45%
BioNTech SE
Mar 13, 2026
Maintained: Buy
Price Target: $155
Current: $94.26
Upside: +64.44%
Legend Biotech
Mar 13, 2026
Maintained: Buy
Price Target: $70
Current: $29.39
Upside: +138.18%
Revolution Medicines
Mar 9, 2026
Maintained: Buy
Price Target: n/a
Current: $192.62
Upside: -
Caribou Biosciences
Mar 9, 2026
Reiterated: Buy
Price Target: $7
Current: $1.77
Upside: +295.48%
Compugen
Mar 3, 2026
Reiterated: Buy
Price Target: $4
Current: $2.16
Upside: +85.19%
Zymeworks
Mar 3, 2026
Reiterated: Buy
Price Target: $40
Current: $24.12
Upside: +65.84%
Septerna
Mar 2, 2026
Maintained: Buy
Price Target: n/a
Current: $34.75
Upside: -
Feb 27, 2026
Reiterated: Buy
Price Target: $30
Current: $31.08
Upside: -3.47%
Feb 25, 2026
Maintained: Hold
Price Target: n/a
Current: $4.21
Upside: -
Feb 25, 2026
Reiterated: Buy
Price Target: $48
Current: $26.02
Upside: +84.47%
Feb 24, 2026
Reiterated: Buy
Price Target: $35
Current: $14.32
Upside: +144.41%
Jan 14, 2026
Reiterated: Buy
Price Target: $51
Current: $54.28
Upside: -6.04%
Jan 13, 2026
Reiterated: Buy
Price Target: $10 → $8
Current: $1.65
Upside: +384.85%
Nov 11, 2025
Maintained: Buy
Price Target: n/a
Current: $33.35
Upside: -
Nov 3, 2025
Reiterated: Buy
Price Target: $127 → $145
Current: $126.33
Upside: +14.78%
Apr 24, 2024
Maintained: Hold
Price Target: n/a
Current: $212.64
Upside: n/a
Mar 21, 2024
Rated: Hold
Price Target: n/a
Current: $7.53
Upside: n/a
Jan 16, 2024
Rated: Hold
Price Target: n/a
Current: $0.6063
Upside: n/a
Aug 23, 2022
Maintained: Buy
Price Target: $19 → $15
Current: $1.75
Upside: n/a
Jul 14, 2022
Maintained: Buy
Price Target: kr 269.14 → kr 347.92
Current: $1,681.64
Upside: n/a